Retrospective Analysis of Effectiveness of Fingolimod in Real Life Setting in Turkey (REFINE)

Background: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs.

Methods: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch. The observation period included three key assessment time points (before the switch, at switch, and after the switch). Data were collected from the MS patients' database by neurologists between January 2018 and June 2019. The longest follow-up period of the patients was determined as 24 months after the switch.

Results: In 462 MS patients that were included in the study, both treatments significantly decreased the number of relapses during the postswitch 12 months versus preswitch one year while patients in the FNG group experienced significantly fewer relapses compared to iDMT cohort in the postswitch 12 months period. FNG cohort experienced fewer relapses than in the iDMT cohort within the postswitch 2 year. The mean time to first relapse after the switch was significantly longer in the FNG group.

Discussion: The present study revealed superior effectiveness of vertical switch over lateral switch regarding the improvement in relapse outcomes. Patients in the FNG cohort experienced sustainably fewer relapses during the follow-up period after the switch compared the iDMT cohort. Importantly, switching to FNG was more effective in delaying time to first relapse when compared with iDMTs.

References

Mazibrada G, Sharples C, Perfect I . Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK. Mult Scler J Exp Transl Clin. 2018; 4(4):2055217318801638. PMC: 6178378. DOI: 10.1177/2055217318801638. View

Confavreux C, Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain. 2006; 129(Pt 3):606-16. DOI: 10.1093/brain/awl007. View

Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G . Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Curr Med Res Opin. 2013; 29(12):1647-56. DOI: 10.1185/03007995.2013.847411. View

Cohen J, Barkhof F, Comi G, Hartung H, Khatri B, Montalban X . Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):402-15. DOI: 10.1056/NEJMoa0907839. View

Calabresi P, Radue E, Goodin D, Jeffery D, Rammohan K, Reder A . Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(6):545-56. DOI: 10.1016/S1474-4422(14)70049-3. View

Weinshenker B, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J . The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989; 112 ( Pt 6):1419-28. DOI: 10.1093/brain/112.6.1419. View

Cree B, Goldman M, Corboy J, Singer B, Fox E, Arnold D . Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2020; . PMC: 7445630. DOI: 10.1001/jamaneurol.2020.2950. View

Kappos L, Radue E, OConnor P, Polman C, Hohlfeld R, Calabresi P . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401. DOI: 10.1056/NEJMoa0909494. View

Comi G, Patti F, Rocca M, Mattioli F, Amato M, Gallo P . Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol. 2017; 264(12):2436-2449. PMC: 5688215. DOI: 10.1007/s00415-017-8642-5. View

10.

Braune S, Grimm S, van Hovell P, Freudensprung U, Pellegrini F, Hyde R . Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018; 265(12):2980-2992. PMC: 6244642. DOI: 10.1007/s00415-018-9083-5. View

11.

Saleem S, Anwar A, Fayyaz M, Anwer F, Anwar F . An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis. Cureus. 2019; 11(7):e5246. PMC: 6759037. DOI: 10.7759/cureus.5246. View

12.

DAmico E, Patti F, Zanghi A, Lo Fermo S, Chisari C, Zappia M . Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Rev Clin Pharmacol. 2018; 11(5):531-536. DOI: 10.1080/17512433.2018.1449643. View

13.

Koch M, Kingwell E, Rieckmann P, Tremlett H . The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010; 81(9):1039-43. DOI: 10.1136/jnnp.2010.208173. View

14.

Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G . Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS One. 2014; 9(2):e88472. PMC: 3916439. DOI: 10.1371/journal.pone.0088472. View

15.

Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017; 17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2. View

16.

Thomas K, Proschmann U, Ziemssen T . Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother. 2017; 18(15):1649-1660. DOI: 10.1080/14656566.2017.1373093. View

17.

Achiron A, Aref H, Inshasi J, Harb M, Alroughani R, Bijarnia M . Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East. BMC Neurol. 2017; 17(1):150. PMC: 5547540. DOI: 10.1186/s12883-017-0913-3. View

18.

Izquierdo G, Damas F, Paramo M, Ruiz-Pena J, Navarro G . The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study. PLoS One. 2017; 12(4):e0176174. PMC: 5409154. DOI: 10.1371/journal.pone.0176174. View

19.

Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L . Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurol Neuroimmunol Neuroinflamm. 2019; 6(3):e548. PMC: 6410931. DOI: 10.1212/NXI.0000000000000548. View

20.

Boster A, Nicholas J, Wu N, Yeh W, Fay M, Edwards M . Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurol Ther. 2017; 6(1):91-102. PMC: 5447557. DOI: 10.1007/s40120-017-0064-x. View